# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...
Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain...
Stifel analyst Bradley Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $8 to ...